Zealand Pharma reports positive phase III results against congenital hyperinsulinism
![Photo: Zealand Pharma / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13878550.ece/ALTERNATES/schema-16_9/doc7kclnpsrsgza4f9n1pk.jpg)
On Thursday, Zealand Pharma has announced positive topline results from a phase III trial of dasiglucagon, a treatment for congenital hyperinsulinism (CHI), the firm reports in a press release.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Zealand Pharma sells insulin pump to Mannkind Corporation
For subscribers
Zealand Pharma rescue pen books USD 0.6m revenue in Q1
For subscribers